如何定义催乳素瘤治疗的成功-一个系统的回顾和理论框架。

IF 5.1
Victoria R van Trigt, Kevin A Huynh, Leontine E H Bakker, Iris C M Pelsma, Ingrid M Zandbergen, Amir H Zamanipoor Najafabadi, Marco J T Verstegen, Wouter R van Furth, Nienke R Biermasz
{"title":"如何定义催乳素瘤治疗的成功-一个系统的回顾和理论框架。","authors":"Victoria R van Trigt, Kevin A Huynh, Leontine E H Bakker, Iris C M Pelsma, Ingrid M Zandbergen, Amir H Zamanipoor Najafabadi, Marco J T Verstegen, Wouter R van Furth, Nienke R Biermasz","doi":"10.1210/clinem/dgaf540","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>As consensus regarding outcome sets for prolactinoma treatment evaluation is lacking, outcome parameters reported in literature were evaluated, and objective, clinically relevant outcome sets were proposed.</p><p><strong>Methods: </strong>A systematic review of studies up to February 2, 2024. Reported biochemical and radiological parameters, clinician-reported findings, patient-reported outcomes (PROs), and definitions of disease remission, control and recurrence were extracted and placed into clinical context. Subsequently, objective and clinically relevant definitions of clinical outcomes were proposed based on the findings, with comprehensive outcome sets to evaluate treatment success.</p><p><strong>Results: </strong>137 articles were included. Albeit ill-defined or subjective, 23 unique prolactin parameters, and 73 unique radiological parameters were reported. Seventy articles included clinician-reported findings, and none reported PROs. Ultimately, 27 unique definitions of remission, 3 unique definitions of disease control, and 20 unique definitions of recurrence were reported. We propose two separate definitions for biochemical and clinical remission/recurrence - either evaluating prolactin levels only, or including symptomology, gonadal function and radiology. Integrated outcome quadrants were illustrated to objectively categorize treatment success by combining achievement of treatment goals with occurrence of adverse effects. A three-tier outcome set based on the Value-Based Healthcare principles was provided.</p><p><strong>Conclusions: </strong>Heterogeneity in reported outcome parameters using varying definitions hamper comparison of prolactinoma treatment outcomes. This study proposes objective, easily applicable, and clinically relevant definitions of clinical outcomes, and offers a comprehensive outcome set. These parameters enable comparison of outcomes across treatment modalities and medical centers to gain insight into this rare disease and improve prolactinoma care.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How to define success in prolactinoma treatment - a systematic review and theoretical framework.\",\"authors\":\"Victoria R van Trigt, Kevin A Huynh, Leontine E H Bakker, Iris C M Pelsma, Ingrid M Zandbergen, Amir H Zamanipoor Najafabadi, Marco J T Verstegen, Wouter R van Furth, Nienke R Biermasz\",\"doi\":\"10.1210/clinem/dgaf540\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>As consensus regarding outcome sets for prolactinoma treatment evaluation is lacking, outcome parameters reported in literature were evaluated, and objective, clinically relevant outcome sets were proposed.</p><p><strong>Methods: </strong>A systematic review of studies up to February 2, 2024. Reported biochemical and radiological parameters, clinician-reported findings, patient-reported outcomes (PROs), and definitions of disease remission, control and recurrence were extracted and placed into clinical context. Subsequently, objective and clinically relevant definitions of clinical outcomes were proposed based on the findings, with comprehensive outcome sets to evaluate treatment success.</p><p><strong>Results: </strong>137 articles were included. Albeit ill-defined or subjective, 23 unique prolactin parameters, and 73 unique radiological parameters were reported. Seventy articles included clinician-reported findings, and none reported PROs. Ultimately, 27 unique definitions of remission, 3 unique definitions of disease control, and 20 unique definitions of recurrence were reported. We propose two separate definitions for biochemical and clinical remission/recurrence - either evaluating prolactin levels only, or including symptomology, gonadal function and radiology. Integrated outcome quadrants were illustrated to objectively categorize treatment success by combining achievement of treatment goals with occurrence of adverse effects. A three-tier outcome set based on the Value-Based Healthcare principles was provided.</p><p><strong>Conclusions: </strong>Heterogeneity in reported outcome parameters using varying definitions hamper comparison of prolactinoma treatment outcomes. This study proposes objective, easily applicable, and clinically relevant definitions of clinical outcomes, and offers a comprehensive outcome set. These parameters enable comparison of outcomes across treatment modalities and medical centers to gain insight into this rare disease and improve prolactinoma care.</p>\",\"PeriodicalId\":520805,\"journal\":{\"name\":\"The Journal of clinical endocrinology and metabolism\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of clinical endocrinology and metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1210/clinem/dgaf540\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of clinical endocrinology and metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf540","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:由于对催乳素瘤治疗评价的结局集缺乏共识,对文献报道的结局参数进行评价,提出客观、临床相关的结局集。方法:对截至2024年2月2日的研究进行系统综述。报告的生化和放射学参数、临床报告的发现、患者报告的结果(PROs)以及疾病缓解、控制和复发的定义被提取出来并置于临床背景中。随后,根据研究结果提出客观和临床相关的临床结果定义,并使用综合结果集来评估治疗成功。结果:纳入137篇文献。尽管定义不清或主观,23个独特的催乳素参数和73个独特的放射学参数被报道。70篇文章包括了临床报告的发现,没有一篇报道了优点。最终,报告了27个缓解的独特定义,3个疾病控制的独特定义和20个复发的独特定义。我们提出两种不同的生化和临床缓解/复发的定义-要么仅评估催乳素水平,要么包括症状,性腺功能和放射学。综合结果象限通过将治疗目标的实现与不良反应的发生相结合,客观地对治疗成功进行分类。提供了基于基于价值的医疗保健原则的三层结果集。结论:使用不同定义的报告结果参数的异质性妨碍了泌乳素瘤治疗结果的比较。本研究提出了客观、易于应用和临床相关的临床结果定义,并提供了一个全面的结果集。这些参数可以比较不同治疗方式和医疗中心的结果,从而深入了解这种罕见疾病并改善催乳素瘤的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
How to define success in prolactinoma treatment - a systematic review and theoretical framework.

Purpose: As consensus regarding outcome sets for prolactinoma treatment evaluation is lacking, outcome parameters reported in literature were evaluated, and objective, clinically relevant outcome sets were proposed.

Methods: A systematic review of studies up to February 2, 2024. Reported biochemical and radiological parameters, clinician-reported findings, patient-reported outcomes (PROs), and definitions of disease remission, control and recurrence were extracted and placed into clinical context. Subsequently, objective and clinically relevant definitions of clinical outcomes were proposed based on the findings, with comprehensive outcome sets to evaluate treatment success.

Results: 137 articles were included. Albeit ill-defined or subjective, 23 unique prolactin parameters, and 73 unique radiological parameters were reported. Seventy articles included clinician-reported findings, and none reported PROs. Ultimately, 27 unique definitions of remission, 3 unique definitions of disease control, and 20 unique definitions of recurrence were reported. We propose two separate definitions for biochemical and clinical remission/recurrence - either evaluating prolactin levels only, or including symptomology, gonadal function and radiology. Integrated outcome quadrants were illustrated to objectively categorize treatment success by combining achievement of treatment goals with occurrence of adverse effects. A three-tier outcome set based on the Value-Based Healthcare principles was provided.

Conclusions: Heterogeneity in reported outcome parameters using varying definitions hamper comparison of prolactinoma treatment outcomes. This study proposes objective, easily applicable, and clinically relevant definitions of clinical outcomes, and offers a comprehensive outcome set. These parameters enable comparison of outcomes across treatment modalities and medical centers to gain insight into this rare disease and improve prolactinoma care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信